MVT-601A-006 MOXIE
Brief description of study
The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
